Ignite Creation Date:
2024-05-05 @ 5:08 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00394082
Status:
COMPLETED
Last Update Posted:
2019-11-25
First Post:
2006-10-30
Brief Title:
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
Sponsor:
Celgene
Organization:
Celgene
Study Overview
Official Title:
A Phase II Trial of Weekly Administration of ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of weekly ABI-007 in combination with bevacizumab
The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab for patients with previously untreated advancedmetastatic breast cancer
The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab for patients with previously untreated advancedmetastatic breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None